Overdosage may lead to excessive diuresis with electrolyte depletion.
A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Duloxetine | The risk or severity of orthostatic hypotension and syncope can be increased when Etacrynic acid is combined with Duloxetine. |
| Levodopa | The risk or severity of hypotension and orthostatic hypotension can be increased when Etacrynic acid is combined with Levodopa. |
| Succinylcholine | The therapeutic efficacy of Succinylcholine can be increased when used in combination with Etacrynic acid. |
| Metocurine iodide | The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Etacrynic acid. |
| Gallamine triethiodide | The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Etacrynic acid. |
| Cisatracurium | The therapeutic efficacy of Cisatracurium can be increased when used in combination with Etacrynic acid. |
| Rocuronium | The therapeutic efficacy of Rocuronium can be increased when used in combination with Etacrynic acid. |
| Atracurium besylate | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Etacrynic acid. |
| Doxacurium | The therapeutic efficacy of Doxacurium can be increased when used in combination with Etacrynic acid. |
| Mivacurium | The therapeutic efficacy of Mivacurium can be increased when used in combination with Etacrynic acid. |
| Decamethonium | The therapeutic efficacy of Decamethonium can be increased when used in combination with Etacrynic acid. |
| Metocurine | The therapeutic efficacy of Metocurine can be increased when used in combination with Etacrynic acid. |
| Pancuronium | The therapeutic efficacy of Pancuronium can be increased when used in combination with Etacrynic acid. |
| Pipecuronium | The therapeutic efficacy of Pipecuronium can be increased when used in combination with Etacrynic acid. |
| Vecuronium | The therapeutic efficacy of Vecuronium can be increased when used in combination with Etacrynic acid. |
| Rapacuronium | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Etacrynic acid. |
| Pyrantel | The therapeutic efficacy of Pyrantel can be increased when used in combination with Etacrynic acid. |
| Neosaxitoxin | The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Etacrynic acid. |
| Atracurium | The therapeutic efficacy of Atracurium can be increased when used in combination with Etacrynic acid. |
| Gallamine | The therapeutic efficacy of Gallamine can be increased when used in combination with Etacrynic acid. |
| Alcuronium | The therapeutic efficacy of Alcuronium can be increased when used in combination with Etacrynic acid. |
| Tubocurarine | The therapeutic efficacy of Tubocurarine can be increased when used in combination with Etacrynic acid. |
| Allopurinol | The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Allopurinol. |
| Canagliflozin | The risk or severity of hypotension can be increased when Canagliflozin is combined with Etacrynic acid. |
| Cisplatin | The risk or severity of ototoxicity and nephrotoxicity can be increased when Etacrynic acid is combined with Cisplatin. |
| Dofetilide | The risk or severity of QTc prolongation, torsade de pointes, hypokalemia, hypomagnesemia, and cardiac arrest can be increased when Etacrynic acid is combined with Dofetilide. |
| Ivabradine | The risk or severity of Cardiac Arrhythmia can be increased when Etacrynic acid is combined with Ivabradine. |
| Lithium citrate | Etacrynic acid may decrease the excretion rate of Lithium citrate which could result in a higher serum level. |
| Lithium carbonate | Etacrynic acid may decrease the excretion rate of Lithium carbonate which could result in a higher serum level. |
| Lithium hydroxide | Etacrynic acid may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level. |
| Methotrexate | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Methotrexate. |
| Probenecid | The risk or severity of adverse effects can be increased when Probenecid is combined with Etacrynic acid. |
| Risperidone | The risk or severity of hypotension can be increased when Etacrynic acid is combined with Risperidone. |
| Topiramate | The risk or severity of hypokalemia can be increased when Etacrynic acid is combined with Topiramate. |
| Foscarnet | Etacrynic acid may decrease the excretion rate of Foscarnet which could result in a higher serum level. |
| Mannitol | The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Etacrynic acid. |
| Tenofovir disoproxil | Etacrynic acid may increase the nephrotoxic activities of Tenofovir disoproxil. |
| Tenofovir alafenamide | Etacrynic acid may increase the nephrotoxic activities of Tenofovir alafenamide. |
| Tenofovir | Etacrynic acid may increase the nephrotoxic activities of Tenofovir. |
| Dicoumarol | The protein binding of Dicoumarol can be decreased when combined with Etacrynic acid. |
| Phenindione | The protein binding of Phenindione can be decreased when combined with Etacrynic acid. |
| Warfarin | The protein binding of Warfarin can be decreased when combined with Etacrynic acid. |
| Phenprocoumon | The protein binding of Phenprocoumon can be decreased when combined with Etacrynic acid. |
| Acenocoumarol | The protein binding of Acenocoumarol can be decreased when combined with Etacrynic acid. |
| 4-hydroxycoumarin | The protein binding of 4-hydroxycoumarin can be decreased when combined with Etacrynic acid. |
| Coumarin | The protein binding of Coumarin can be decreased when combined with Etacrynic acid. |
| (R)-warfarin | The protein binding of (R)-warfarin can be decreased when combined with Etacrynic acid. |
| Ethyl biscoumacetate | The protein binding of Ethyl biscoumacetate can be decreased when combined with Etacrynic acid. |
| Fluindione | The protein binding of Fluindione can be decreased when combined with Etacrynic acid. |
| Clorindione | The protein binding of Clorindione can be decreased when combined with Etacrynic acid. |
| Diphenadione | The protein binding of Diphenadione can be decreased when combined with Etacrynic acid. |
| Tioclomarol | The protein binding of Tioclomarol can be decreased when combined with Etacrynic acid. |
| (S)-Warfarin | The protein binding of (S)-Warfarin can be decreased when combined with Etacrynic acid. |
| Aripiprazole | Aripiprazole may increase the hypotensive activities of Etacrynic acid. |
| Aripiprazole lauroxil | Aripiprazole lauroxil may increase the hypotensive activities of Etacrynic acid. |
| Nicorandil | Nicorandil may increase the hypotensive activities of Etacrynic acid. |
| Acetyldigitoxin | The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Acetyldigitoxin. |
| Deslanoside | The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Deslanoside. |
| Ouabain | The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Ouabain. |
| Digitoxin | The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Digitoxin. |
| Oleandrin | The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Oleandrin. |
| Cymarin | The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Cymarin. |
| Proscillaridin | The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Proscillaridin. |
| Metildigoxin | The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Metildigoxin. |
| Lanatoside C | The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Lanatoside C. |
| Gitoformate | The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Gitoformate. |
| Acetyldigoxin | The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Acetyldigoxin. |
| Peruvoside | The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Peruvoside. |
| Digoxin | The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Digoxin. |
| Cyclosporine | The risk or severity of adverse effects can be increased when Cyclosporine is combined with Etacrynic acid. |
| Icosapent | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Icosapent. |
| Mesalazine | The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Etacrynic acid. |
| Nabumetone | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Nabumetone. |
| Ketorolac | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Ketorolac. |
| Tenoxicam | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tenoxicam. |
| Celecoxib | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Celecoxib. |
| Tolmetin | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tolmetin. |
| Rofecoxib | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Rofecoxib. |
| Piroxicam | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Piroxicam. |
| Fenoprofen | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Fenoprofen. |
| Valdecoxib | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Valdecoxib. |
| Diclofenac | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Diclofenac. |
| Sulindac | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Sulindac. |
| Flurbiprofen | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Flurbiprofen. |
| Etodolac | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Etodolac. |
| Mefenamic acid | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Mefenamic acid. |
| Naproxen | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Naproxen. |
| Sulfasalazine | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Sulfasalazine. |
| Phenylbutazone | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Phenylbutazone. |
| Carprofen | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Carprofen. |
| Diflunisal | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Diflunisal. |
| Salicylic acid | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Salicylic acid. |
| Meclofenamic acid | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Meclofenamic acid. |
| Oxaprozin | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Oxaprozin. |
| Ketoprofen | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Ketoprofen. |
| Balsalazide | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Balsalazide. |
| Ibuprofen | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Ibuprofen. |
| Olsalazine | The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Olsalazine. |
| Lumiracoxib | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Lumiracoxib. |
| Magnesium salicylate | The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Magnesium salicylate. |